MARKET

COGT

COGT

Cogent Biosciences Inc
NASDAQ
33.10
+0.48
+1.47%
After Hours: 33.33 +0.23 +0.69% 17:48 06/12 EDT
OPEN
32.58
PREV CLOSE
32.62
HIGH
33.53
LOW
32.33
VOLUME
1.48M
TURNOVER
--
52 WEEK HIGH
43.73
52 WEEK LOW
6.59
MARKET CAP
5.66B
P/E (TTM)
-15.3718
1D
5D
1M
3M
1Y
5Y
1D
Cogent Biosciences (COGT) Is Up 6.7% After Positive PEAK Trial Data and FDA Priority Review - What's Changed
Simply Wall St · 20h ago
COGENT BIOSCIENCES - TO SUBMIT APEX NDA IN JUNE 2026
Reuters · 1d ago
Cogent Biosciences says mutant-selective JAK2 V617F inhibitor CGT1145 on track for IND in 2026
PUBT · 1d ago
Cogent says bezuclastinib posts 65% response rate in APEX trial for advanced systemic mastocytosis
PUBT · 1d ago
Cogent Biosciences Shareholders Back Board, Governance Proposals
TipRanks · 1d ago
Assessing Cogent Biosciences (COGT) Valuation After A Strong One Year Run And Cooling Momentum
Simply Wall St · 4d ago
Weekly Report: what happened at COGT last week (0601-0605)?
Weekly Report · 5d ago
Compass Pathways targets late 2027 approval for treatment-resistant depression psychedelic therapy
PUBT · 06/05 13:21
More
About COGT
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.

Webull offers Cogent Biosciences Inc stock information, including NASDAQ: COGT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COGT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading COGT stock methods without spending real money on the virtual paper trading platform.